Recent Blog Posts

View Post: Triple versus single therapy in COPD « NPCi blog
4 Nov 2009 by bowersc  
A short-term randomised controlled trial claims benefits for the addition of inhaled budesonide/formoterol to tiotropium (i.e. triple vs. single therapy) in patients with COPD. However, limitations of the study question its ... A one-year study of 449 patients with moderate or severe COPD, which found that adding salmeterol or salmeterol/fluticasone to tiotropium did not reduce exacerbations in people with moderate to severe COPD. However, some statistically significant ...
View Blog: NPCi blog - http://www.npci.org.uk/blog/

---

View Post: Respiratory Research
Full text
The bioavailability and airway ... ...
View Blog: The bioavailability and airway clearance of the steroid component of budesonide/formoterol and salmeterol/fluticasone after inhaled administration in patients with COPD and healthy subjects: a randomized controlled trial ... Although these combinations both contain an ICS and a LABA, differences exist with regard to the pharmacokinetic and pharmacodynamic properties of both components, such as the oral bioavailability and clearance, volume of distribution and speed of

---

View Post: Salmeterol/Fluticasone Reduces COPD Exacerbations Better Than ...
17 Jan 2007
January 17, 2006 -- Salmeterol/fluticasone combination therapy might reduce exacerbations in patients with severe chronic obstructive pulmonary disease (COPD) to a greater extent than salmeterol alone, according to the results of a randomized, ... "Treatment benefits from ICS [inhaled corticosteroids] in patients with COPD are primarily related to reducing exacerbations among patients who are exacerbation prone and who have severe to very severe disease (FEV 1 [forced ...
View Blog: Medscape Headlines - http://www.medscape.com/home

---

View Post: EuroPharma Today: Boehringer Finds COPD Exacerbation Studies Can ...
23 Sep 2009 by Sean  
... for Spiriva HandiHaler (tiotropium inhalation powder) to include its use against exacerbation of chronic obstructive pulmonary disease, something GlaxoSmithKline's market-leading Advair (fluticasone/salmeterol inhalation powder) did in 2008 that put it in a league of its own. ... Forest Laboratories recently inked a deal with Nycomed as its commercialization partner for Daxas (roflumilast), a promising oral COPD drug, which recently turned up positive Phase II data. ...
View Blog: EuroPharma Today - http://www.europharmatoday.com/

---

View Post: Salmeterol Plus Fluticasone May Be Preferred to Tiotropium for COPD
28 Dec 2007
"Treatment with SFC and tiotropium achieved similar exacerbation rates with different mechanisms (as evidenced by the difference in use of oral corticosteroids and antibiotics to treat HCU exacerbations), and this resulted in different outcomes," the .... Compare outcomes of chronic obstructive pulmonary disease exacerbations for 2 years between inhaled salmeterol with fluticasone and tiotropium in patients with severe to very severe chronic obstructive pulmonary disease. ...
View Blog: Medscape Nurses Headlines - http://www.medscape.com/nurses?src=rss

---

View Post: FDA Safety Changes: Visicol and Advair Diskus
21 Jun 2006
The FDA has approved revisions to the safety labeling for sodium phosphate monobasic monohydrate plus sodium phosphate dibasic anhydrous tablets and fluticasone plus salmeterol inhalation powder. ... twice-daily use in the maintenance treatment of asthma in patients aged 4 years and older. The 250-µg/50-µg formulation is indicated for the twice-daily treatment of airflow obstruction in patients with chronic obstructive pulmonary disease associated with chronic bronchitis . ...
View Blog: Medscape Gastroenterology Headlines - http://www.medscape.com/gastroenterology

---

View Post: Advair Diskus (Fluticasone Propionate) Drug Information: Uses ...
19 Jun 2008
Disposable purple device with 60 blisters containing a combination of fluticasone propionate (100, 250, or 500 mcg) and salmeterol (50 mcg) as an oral inhalation powder formulation. An institutional pack containing 14 ..... Lower respiratory tract infections, including pneumonia, have been reported in patients with COPD following the inhaled administration of corticosteroids, including fluticasone propionate and ADVAIR DISKUS. In 2 replicate 12-month studies of 1579 ...
View Blog: RxList - News and Features - http://www.rxlist.com/script/main/hp.asp

---

View Post: FDA warns of stolen albuterol sulfate and ipratropium bromide ...
18 Sep 2009
The FDA has advised consumers not to use albuterol sulfate inhalation solution, 0.083%, and ipratropium bromide inhalation solutions, 0.02%, unit-dose vials, purchased after September 8, 2009 and manufactured by Dey LP, a subsidiary of Mylan, because the medications might have ... Nycomed announced the submission of a New Drug Application (NDA) to the FDA for Daxas (roflumilast) as a once-daily oral treatment for symptomatic chronic obstructive pulmonary disease (COPD). ...
View Blog: Latest articles from MPR - http://www.empr.com/

---

View Post: FDA Safety Changes: Advair Diskus and Vfend
20 Aug 2008
The FDA has approved revisions to the safety labeling for fluticasone propionate plus salmeterol xinafoate inhalation powder and voriconazole tablets, injection, and oral suspension. ... In 2 replicate 12-month COPD studies (n = 1579), use of inhaled fluticasone plus salmeterol (250 µg/50 µg) was linked to an increased incidence of pneumonia vs salmeterol 50 µg alone (7% vs 3%), particularly in patients aged older than 65 years (9% vs 4%). These findings were supported by ...
View Blog: Medscape Pulmonary Medicine Headlines - http://www.medscape.com/pulmonarymedicine

---

View Post: USPharmacist.com > Management Strategies in Stable COPD
26 Jan 2009
Oral Glucocorticosteroids: It has often been recommended to use a short-term treatment, usually two weeks, of oral glucocorticosteroids to predict the potential for benefit of long-term treatment with oral or inhaled glucocorticosteroids in COPD patients.41 .... Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med. 2007;356:775-789. 39. FDA approves Advair 250/50 for reduction of exacerbations in patients with COPD. ...
View Blog: Untitled - http://www.uspharmacist.com/home/

---